1Parkin DM. International variation[J]. Oneogene, 2004, 23(38 ) :6329-6340.
2Greenlee RT, Murray T, Bolden S, et al. Cancer statistics,2000[J]. CA Cancer J Clin, 2000,50(1 ): 7-33.
3Ajani JA,Fairweather J, Dumas P, et al. Phase Ⅱ study of taxol in patients with advanced gastric carcinoma[J].Cancer J Sci Am,1998,4(4):269-274.
4Ajani JA. Docetaxet in combination for advanced gastric cancer[J].Gastric Cancer,2002,5(Suppl 1):31-34.
5Koizumi W,Saigenji K,Ujiie S, et al. A pilot phase Ⅱ study of capecitabine in advanced or recurrent gastric cancer[J].Oncology, 2003, 64(3):232-236.
6Koizumi W, Kurihara M, Nakano S, et al. Phase Ⅱ study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group[J ]. Ontology, 2000,58 (3): 191-197.
7Chollet P, Schoffski P, Weigang-Kohler K, et al. Phase Ⅱ trial of S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG)[J]. Eur J Cancer, 2003,39(9):1264-1270.
8Enzinger P, Kulke M, Clark J, et al. Phase Ⅱ trial of CPT-11 in previously untreated patients with advanced adenocarcinoma of the esophagus and stomach[J]. Proc Am Soc Clin Oncol, 2000,19(abstr 1243).
9Lin IS, Hecht J. A phase Ⅱ trial of irinotecan in patients with advanced adenocarcinoma of the gastroesophageal(GE) junction[J]. Proc Am Soc Clin Oncol, 2000, 19 (abstr 1130).
10Wils JA, Klein HO, Wagener DJ, et al. Sequential highdose methotrexate and fluorouracil combined with doxorubicin-a step ahead in the treatment of advanced gastriccancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group[J]. J Clin Oncol, 1991, 9(5):827-831.
